Hypogonadism

Latest News

First Testosterone Undecanoate Softgel Approved by FDA for Hypogonadism

By

Steve Duffy

Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.

ACP Issues Guidelines for Use of Testosterone Therapy in Age-Related Low Testosterone

By

Rachael Beairsto

The American College of Physicians has issued a set of recommendations to clarify the potential benefits and harms of testosterone therapy in men with age-related low testosterone.

Waist Circumference Affects Coronary Plaque Accumulation in Testosterone Therapy

By

Amit Akirov, MD

Older men receiving testosterone treatment with higher waist-to-hip ratio experience greater increases in noncalcified coronary plaque volume.

Short-Term Testosterone Therapy Associated With VTE Risk in Men

For men with and without hypogonadism, testosterone therapy is associated with an increased short-term risk for venous thromboembolism.

Suboptimal Screening for Hypogonadism in Men Receiving Opioids

More men with long-term opioid use are screened for low testosterone than men taking opioids for a short period of time; however, given the known link between opioid use and low testosterone, these rates were still lower than expected.

Testosterone Undecanoate May Reduce CV Morbidity, Mortality in Men With Hypogonadism, Type 2 Diabetes

By

Amit Akirov, MD

Long-term treatment with testosterone undecanoate was associated with reduced cardiovascular morbidity and mortality in patients with hypogonadism and type 2 diabetes.

Genetically Determined Low Vitamin D Concentrations Associated With Low Testosterone Levels

By

Amit Akirov, MD

Genetically low 25-hydroxyvitamin D levels are associated with lower testosterone levels.

Testosterone Deficiencies Common in Men With Hepatitis C Virus Infection

By

Hannah Dellabella

In a subanalysis, researchers discovered that testosterone deficiency was common in men with a sustained virologic response after being treated for hepatitis C.

Testosterone Replacement in Congenital Hypogonadotropic Hypogonadism Has Limited Effects on Bone Health

By

Tyler Rice

Testosterone replacement therapy prevents further bone loss at the lumbar and femoral levels in patients with congenital hypogonadotropic hypogonadism, but it does not reliably elevate bone mineral density out of the osteopenic/osteoporotic range.

New Oral Treatment Approved for Men With Certain Types of Hypogonadism

By

Da Hee Han, PharmD

The Food and Drug Administration (FDA) has approved Jatenzo (testosterone undecanoate; Clarus Therapeutics) capsules for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: congenital or acquired primary hypogonadism or hypogonadotropic hypogonadism.

Testosterone Therapy Prevents Progression From Prediabetes to T2D in Hypogonadism

Men with prediabetes, hypogonadism achieved normal glucose regulation with TTh